Bringing the fundamentals into focus…
Back to Collegium Pharmaceutical, Inc.
How Collegium Pharmaceutical, Inc. stacks up
COLL · against 485 other Healthcare companies of similar size
Valuation
92/ 100
Near the top of its peers.
Ranked #41 of 486 · scores higher than 92% of peers
Bars: peers in each 10-point band of the valuation score54 peers with a valuation score of 90–100, including COLL · Click a bar to see the companies
Why valuation scores 92?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its free cash flow yield, EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
- higher earnings for the price paid: stronger than 80% of peers. Earnings yield: 6.2% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 95% of peers. EBITDA yield: 21.8% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 99% of peers. Free cash flow yield: 42.5% vs peer median 0.0%
Metric by metric
Position: dot = COLL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | COLL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 474 reported | 5.4% | 1.1% | 80% | 30% | |
| EBITDA yieldHigher is better · 492 reported | 21.8% | 3.8% | 96% | 50% | |
| Free cash flow yieldHigher is better · 202 reported | 42.5% | -3.5% | 100% | 20% | |
| Book yieldHigher is better · 483 reported | 40.4% | 43.8% | 46% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around COLLScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score